Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan Restasis approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Allergan's Restasis (cyclosporine ophthalmic emulsion 0.5%) clears FDA Dec. 23 for treatment of keratoconjunctivitis sicca (chronic dry eyes) after a protracted review. The original Feb. 24, 1999 NDA was granted priority status, but review was complicated by a unanimous advisory committee vote against approval in July 1999 and three "approvable" letters. In the NDA's four studies comparing Restasis to vehicle in 1,200 patients, a statistically significant increase in Schirmer wetting at six months was seen in 15% of Restasis patients. The agent will be available in early Apri

You may also be interested in...

What’s Next? Five Things To Look Out For In March

In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.

Sensyne Algorithm For COVID-19 Risk Prediction Gets UK Regulatory Approval

Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.

Slovakia Becomes Second EU Country To OK Use Of Russian Vaccine

While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts